

# The role of digital technologies and AI in supporting clinical decision and driving personalized diabetes care

## -The perspective of healthcare professionals

**Dr Sufyan Hussain**

Consultant Physician in Diabetes and Endocrinology and Honorary  
Senior Clinical Lecturer

Guy's and St Thomas' NHS Foundation Trust & King's College London



@sugarydoc

IDF Europe 2021 @sugarydoc

# Disclosures

- I have received honorarium for non-promotional educational talks from Novo Nordisk
- The slides and views expressed are my own
- Personal experience of living and using diabetes technologies for ~30 years

# The Problem?


**537 million**  
adults are living with diabetes

**4 in 5**  
adults with diabetes  
live in low- and middle-income countries

**6.7 million**  
deaths due to diabetes in 2021



Highest number of children and adolescents -295,000  
Second highest average cost per person with diabetes (\$3086)




# Solutions?

Maximising value by  
using resources  
optimally

AI and devices key  
enablers


Population health managers will be incented to push activity  
out of high-cost settings and into the daily lives of consumers



Source: Oliver Wyman analysis


<http://owy.mn/1MjxsKA>

# Clinical decision making – Remote follow-up




Consultations	Face-to-face	Video	Telephone	p value
Average mins per consultation	30 (20-36)	30 (20-30)	20 (15-30)	<0.001

May not save time but offers ability to reach out further and operational cost savings



# Clinical decision making – App based management

- Smartphone based apps in diabetes management
- Example during gestational diabetes in pregnancy
  - High-frequency visits reduced
  - Regular feedback and optimisation






# Clinical decision making – Artificial intelligence


Need for ecosystem with “clean data”

Diabetes retinal screening

Improved decision making




# Diabetes Technologies



Flash glucose monitoring

## CGM



Insulin pumps (CSII)




“Smart” pens



# Can diabetes devices improve outcomes?

## U.S. T1D Exchange registry data




# Artificial intelligence paves the way for fully automated diabetes kit


'DIY' monitoring systems are one answer to regulatory delays



Safe zone: programmable insulin pumps help keep blood sugar at the right level



# Automated insulin delivery systems





**Hybrid closed loops  
Or  
“Artificial Pancreas systems”**

**4 Commercial Systems in the UK**



# Artificial pancreas systems in T2DM on HD

## MDI and CGM



TDD 88 units of insulin  
Insulatard 32 units AM 22 units PM  
Novorapid 10/10/12 units


## CAM APS HX system



TDD 79 units of insulin

## Non-dialysis day


Sunday 10/11



Basal 64.8U, 100% Bolus 0U, 0%


Time	U/h
00:18	0.250
00:18	0.200
00:30	1.870
00:38	2.250
00:38	2.050
00:46	3.250
00:58	2.000
01:10	0.750

Time	U
------	---



## Dialysis day


Wednesday 13/11



Basal 78.6U, 100% Bolus 0U, 0%

Time	U/h
00:34	0.250
00:34	0.200
00:46	0.250
00:46	0.200
00:58	0.000
01:22	0.250
01:34	1.130
01:34	1.100

Time	U
------	---



# Inverse care low and inequality gaps in technology access

Devices – expense, require digital & health literacy

## THE INVERSE CARE LAW

JULIAN TUDOR HART


*Glyncorrwg Health Centre, Port Talbot, Glamorgan, Wales*

**Summary** The availability of good medical care tends to vary inversely with the need for it in the population served. This inverse care law operates more completely where medical care is most exposed to market forces, and less so where such exposure is reduced. The market distribution of medical care is a primitive and historically outdated social form, and any return to it would further exaggerate the maldistribution of medical resources.

## Deprivation and access to CSII (insulin pumps)

The number of people using pumps decreases with increasing levels of deprivation.

Figure 5: The percentage in each IMD quintile for people on pump, compared to those not on pump, Type 1 diabetes, England and Wales, 2016-17



## National Diabetes Insulin Pump Audit Report, 2016-17




Figure 68: Percentage of children and young people with Type 1 Diabetes using Insulin Pump Therapy by ethnic group and deprivation, 2019/20



# Tackling access & digital literacy

KEY PRIORITY

STRONG IMPLICATIONS FOR TYPE 2 DIABETES


## Non-invasive glucose monitoring



## Lower cost sensors



## Lower cost pumps



Forlenza G 23 May 2019

<https://doi.org/10.1089/dia.2019.0077>


# The future?

## Combining personal digital technologies with AI


- Detection of derangements in glucose and adverse glycaemic events
- Insulin bolus calculation and advisory
  - Retinal screening

## Working with care systems

- Prediction and clinical decision making



# Thank you!



Courtesy of Dr Rayhan Lal

**NHS**  
Guy's and St Thomas'  
NHS Foundation Trust



 KING'S  
HEALTH  
PARTNERS

**DTN UK**  
collaborate · evolve · support